We are live on
!
Find out more
BC
Broadwood Capital Portfolio holdings
AUM
$1.42B
1-Year Est. Return
34.72%
This Fund
S&P 500
This Quarter
Est. Return
+14.88%
1 Year Est. Return
+34.72%
3 Year Est. Return
+45.97%
5 Year Est. Return
+44.27%
10 Year Est. Return
+866.96%
AUM
$594M
AUM Growth
+$85.7M
(+17%)
Cap. Flow
+$21.7M
Cap. Flow
% of AUM
3.65%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
2
Increased
3
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMPR
IMPRIVATA, INC COM
IMPR
|
+$7.88M |
| 2 |
Lineage Cell Therapeutics
LCTX
|
+$5.93M |
| 3 |
CYNO
Cynosure, Inc. Class A
CYNO
|
+$817K |
| 4 |
STAAR Surgical
STAA
|
+$238K |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 45.8% |
| 2 | Consumer Staples | 40.13% |
| 3 | Technology | 1.27% |
Similar funds
PTC
NI
CBA
KC
EWS
IHG
SCM
PPC
Broadwood Capital's Q4 2015 Portfolio in Review
As of Q4 2015, Broadwood Capital held 9 positions worth $594M, up 17% from $508M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Broadwood Capital deployed $21.7M of net new capital in Q4 2015, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was IMPRIVATA, INC COM: 668,526 shares worth $7.55M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier, followed by Consumer Staples and Technology.
- Broadwood Capital's largest Q4 2015 buy was IMPRIVATA, INC COM: 668,526 shares worth $7.55M.
- Broadwood Capital added most to Lineage Cell Therapeutics in Q4 2015, an estimated $5.93M increase.
- Broadwood Capital's ten largest holdings make up 100% of its $594M portfolio in Q4 2015.
- Broadwood Capital opened 2 new positions and closed 0 in Q4 2015.
- Broadwood Capital's portfolio value rose 17% quarter-over-quarter to $594M.
Based on Broadwood Capital's 13F filing for Q4 2015, filed 16 Feb 2016.